Base de datos : MEDLINE
Búsqueda : sida or vih [Palabras]
Referencias encontradas : 289008 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 28901 va a la página                         

  1 / 289008 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
PubMed Central Texto completo
Texto completo
[PMID]:25919393
[Au] Autor:Eriksson EM; Liegler T; Keh CE; Karlsson AC; Holditch SJ; Pilcher CD; Loeb L; Nixon DF; Hecht FM
[Ad] Dirección:Division of Experimental Medicine, Department of Medicine, University of California, San Francisco Positive Health Program, San Francisco General Hospital, San Francisco, California....
[Ti] Título:Newly Exerted T Cell Pressures on Mutated Epitopes following Transmission Help Maintain Consensus HIV-1 Sequences.
[So] Fuente:PLoS One;10(4):e0120787, 2014.
[Is] ISSN:1932-6203
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:CD8+ T cells are important for HIV-1 virus control, but are also a major contributing factor that drives HIV-1 virus sequence evolution. Although HIV-1 cytotoxic T cell (CTL) escape mutations are a common aspect during HIV-1 infection, less is known about the importance of T cell pressure in reversing HIV-1 virus back to a consensus sequences. In this study we aimed to assess the frequency with which reversion of transmitted mutations in T cell epitopes were associated with T cell responses to the mutation. This study included 14 HIV-1 transmission pairs consisting of a 'source' (virus-donor) and a 'recipient' (newly infected individual). Non-consensus B sequence amino acids (mutations) in T cell epitopes in HIV-1 gag regions p17, p24, p2 and p7 were identified in each pair and transmission of mutations to the recipient was verified with population viral sequencing. Longitudinal analyses of the recipient's viral sequence were used to identify whether reversion of mutations back to the consensus B sequence occurred. Autologous 12-mer peptides overlapping by 11 were synthesized, representing the sequence region surrounding each reversion and longitudinal analysis of T cell responses to source-derived mutated and reverted epitopes were assessed. We demonstrated that mutations in the source were frequently transmitted to the new host and on an average 17 percent of mutated epitopes reverted to consensus sequence in the recipient. T cell responses to these mutated epitopes were detected in 7 of the 14 recipients in whom reversion occurred. Overall, these findings indicate that transmitted non-consensus B epitopes are frequently immunogenic in HLA-mismatched recipients and new T cell pressures to T cell escape mutations following transmission play a significant role in maintaining consensus HIV-1 sequences.
[Mh] Términos MeSH primario: Epítopos de Linfocito T/genética
Infecciones por VIH/transmisión
VIH-1/genética
Mutación
Linfocitos T Citotóxicos/inmunología
[Mh] Términos MeSH secundario: Linfocitos T CD8-positivos/inmunología
Secuencia de Consenso
Evolución Molecular
Infecciones por VIH/inmunología
Infecciones por VIH/virología
VIH-1/inmunología
Humanos
ARN Viral/análisis
Análisis de Secuencia de ARN
Productos del Gen gag del Virus de la Inmunodeficiencia Humana/genética
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (Epitopes, T-Lymphocyte); 0 (RNA, Viral); 0 (gag Gene Products, Human Immunodeficiency Virus)
[Em] Mes de ingreso:1601
[Cu] Fecha actualización por clase:160123
[Lr] Fecha última revisión:160123
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:150429
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0120787


  2 / 289008 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:26436616
[Au] Autor:Silverberg MJ; Lau B; Achenbach CJ; Jing Y; Althoff KN; D'Souza G; Engels EA; Hessol NA; Brooks JT; Burchell AN; Gill MJ; Goedert JJ; Hogg R; Horberg MA; Kirk GD; Kitahata MM; Korthuis PT; Mathews WC; Mayor A; Modur SP; Napravnik S; Novak RM; Patel P; Rachlis AR; Sterling TR; Willig JH; Justice AC; Moore RD; Dubrow R; North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS
[Ti] Título:Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study.
[So] Fuente:Ann Intern Med;163(7):507-18, 2015 Oct 6.
[Is] ISSN:1539-3704
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Cancer is increasingly common among persons with HIV. OBJECTIVE: To examine calendar trends in cumulative cancer incidence and hazard rate by HIV status. DESIGN: Cohort study. SETTING: North American AIDS Cohort Collaboration on Research and Design during 1996 to 2009. PARTICIPANTS: 86 620 persons with HIV and 196 987 uninfected adults. MEASUREMENTS: Cancer type-specific cumulative incidence by age 75 years and calendar trends in cumulative incidence and hazard rates, each by HIV status. RESULTS: Cumulative incidences of cancer by age 75 years for persons with and without HIV, respectively, were as follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.5% and 0.7%; lung cancer, 3.4% and 2.8%; anal cancer, 1.5% and 0.05%; colorectal cancer, 1.0% and 1.5%; liver cancer, 1.1% and 0.4%; Hodgkin lymphoma, 0.9% and 0.09%; melanoma, 0.5% and 0.6%; and oral cavity/pharyngeal cancer, 0.8% and 0.8%. Among persons with HIV, calendar trends in cumulative incidence and hazard rate decreased for Kaposi sarcoma and non-Hodgkin lymphoma. For anal, colorectal, and liver cancer, increasing cumulative incidence, but not hazard rate trends, were due to the decreasing mortality rate trend (-9% per year), allowing greater opportunity to be diagnosed. Despite decreasing hazard rate trends for lung cancer, Hodgkin lymphoma, and melanoma, cumulative incidence trends were not seen because of the compensating effect of the declining mortality rate. LIMITATION: Secular trends in screening, smoking, and viral co-infections were not evaluated. CONCLUSION: Cumulative cancer incidence by age 75 years, approximating lifetime risk in persons with HIV, may have clinical utility in this population. The high cumulative incidences by age 75 years for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer support early and sustained antiretroviral therapy and smoking cessation.
[Mh] Términos MeSH primario: Infecciones por VIH/epidemiología
Neoplasias/epidemiología
[Mh] Términos MeSH secundario: Adulto
Distribución por Edad
Anciano
Neoplasias del Ano/epidemiología
Estudios de Cohortes
Neoplasias Colorrectales/epidemiología
Comorbilidad
Femenino
Humanos
Incidencia
Neoplasias Hepáticas/epidemiología
Neoplasias Pulmonares/epidemiología
Linfoma no Hodgkin/epidemiología
Masculino
Mediana Edad
América del Norte/epidemiología
Modelos de Riesgos Proporcionales
Sarcoma de Kaposi/epidemiología
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Em] Mes de ingreso:1601
[Cu] Fecha actualización por clase:160122
[Lr] Fecha última revisión:160122
[Sb] Subgrupo de revista:AIM; IM
[Da] Fecha de ingreso para procesamiento:151006
[St] Status:MEDLINE
[do] DOI:10.7326/M14-2768


  3 / 289008 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:25762788
[Au] Autor:Abraham AG; Darilay A; McKay H; Margolick JB; Estrella MM; Palella FJ; Bolan R; Rinaldo CR; Jacobson LP
[Ad] Dirección:Department of Epidemiology....
[Ti] Título:Kidney Dysfunction and Markers of Inflammation in the Multicenter AIDS Cohort Study.
[So] Fuente:J Infect Dis;212(7):1100-10, 2015 Oct 1.
[Is] ISSN:1537-6613
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Human immunodeficiency virus (HIV)-infected individuals are at higher risk for chronic kidney disease than HIV-uninfected individuals. We investigated whether the inflammation present in treated HIV infection contributes to kidney dysfunction among HIV-infected men receiving highly active antiretroviral therapy. METHODS: The glomerular filtration rate (GFR) was directly measured (using iohexol) along with 12 markers of inflammation in Multicenter AIDS Cohort Study participants. Exploratory factor analysis was used to identify inflammatory processes related to kidney dysfunction. The estimated levels of these inflammatory processes were used in adjusted logistic regression analyses evaluating cross-sectional associations with kidney function outcomes. RESULTS: There were 434 HIV-infected men receiving highly active antiretroviral therapy and 200 HIV-uninfected men. HIV-infected men were younger (median age, 51 vs 53 years) and had higher urine protein-creatinine ratios (median, 98 vs 66 mg/g) but comparable GFRs (median, 109 vs 106 mL/min|1.73 m(2)). We found an inflammatory process dominated by markers: soluble tumor necrosis factor receptor 2, soluble interleukin 2 receptor α, soluble gp130, soluble CD27, and soluble CD14. An increase of 1 standard deviation in that inflammatory process was associated with significantly greater odds of GFR ≤90 mL/min/1.73 m(2) (odds ratio, 2.0) and urine protein >200 mg/g (odds ratio, 2.3). CONCLUSIONS: Higher circulating levels of immune activation markers among treated HIV-infected men may partially explain their higher burden of kidney dysfunction compared with uninfected men.
[Mh] Términos MeSH primario: Infecciones por VIH/complicaciones
Infecciones por VIH/quimioterapia
Insuficiencia Renal Crónica/etiología
[Mh] Términos MeSH secundario: Terapia Antirretroviral Altamente Activa
/análisis
Estudios de Cohortes
Estudios Transversales
Análisis Factorial
Tasa de Filtración Glomerular
Homosexualidad Masculina
Humanos
Inflamación/complicaciones
Inflamación/diagnóstico
Masculino
Mediana Edad
Oportunidad Relativa
Estudios Prospectivos
Insuficiencia Renal Crónica/fisiopatología
Factores de Riesgo
[Pt] Tipo de publicación:JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nombre de substancia:
0 (Biomarkers)
[Em] Mes de ingreso:1601
[Cu] Fecha actualización por clase:160122
[Lr] Fecha última revisión:160122
[Sb] Subgrupo de revista:AIM; IM
[Da] Fecha de ingreso para procesamiento:150904
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jiv159


  4 / 289008 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:24623475
[Au] Autor:Weiss SM; Tobin JN; Lopez M; Simons H; Cook R; Jones DL
[Ad] Dirección:Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Dominion Tower, Suite 404A, 1400 NW 10th Avenue, Miami, FL, 33136, USA, sweiss2@med.miami.edu.
[Ti] Título:Translating an Evidence-Based Behavioral Intervention for Women Living with HIV into Clinical Practice: The SMART/EST Women's Program.
[So] Fuente:Int J Behav Med;22(3):415-24, 2015 Jun.
[Is] ISSN:1532-7558
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: The process of translating scientific findings into clinical and public health settings has only recently received priority attention within the scientific community. PURPOSE: Fueled by "Funding Opportunity Announcements" from the National Institutes of Health and Centers for Disease Control and Prevention, scientists have begun to explore the pathways to effectively "transfer" promising research accomplishments into effective and sustainable service programs within the health care delivery system. METHOD: Using Glasgow's RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance) model as a guide, this research team enrolled 428 socially disadvantaged, culturally diverse women living with HIV/AIDS to test the dissemination and implementation of an evidence-based behavioral intervention designed to improve and sustain the physical and emotional health of participants into the Community Health Center (CHC) setting when conducted by trained CHC staff. RESULTS: Findings demonstrate the ability of trained CHC staff group leaders to attain results equivalent or superior to those achieved when conducted by research staff on the three principal study outcomes: depression, medication adherence and HIV viral load. Four of five CHCs involved in the study also identified and successfully obtained funding to continue to run intervention groups, supporting the adoption and sustainability components of the translation model. CONCLUSION: This study confirmed (a) the "translatability" of the Stress Management And Relaxation Training/Emotional Supportive Therapy (SMART/EST) Women's Program, from academic to CHC settings in two geographic regions with high HIV prevalence among women, (b) the ability of local staff (using the "train the trainer" model) to successfully achieve program fidelity and clinical outcomes, and (c) the sustainability the program beyond the auspices of research support, through supportive CHC leadership securing continued program funding.
[Mh] Términos MeSH primario: Terapia Conductista/métodos
Prestación de Atención de Salud/organización & administración
Infecciones por VIH/terapia
[Mh] Términos MeSH secundario: Adulto
Medicina Basada en Evidencia/organización & administración
Femenino
Humanos
Liderazgo
Mediana Edad
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Em] Mes de ingreso:1512
[Cu] Fecha actualización por clase:160122
[Lr] Fecha última revisión:160122
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:150530
[St] Status:MEDLINE
[do] DOI:10.1007/s12529-014-9399-1


  5 / 289008 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
PubMed Central Texto completo
Texto completo
[PMID]:24604206
[Au] Autor:Jones D; Weiss S; Chitalu N
[Ad] Dirección:Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, 1400 NW 10th Avenue, Suite 404A, Miami, FL, 33136, USA, djones@med.miami.edu.
[Ti] Título:HIV Prevention in Resource Limited Settings: A Case Study of Challenges and Opportunities for Implementation.
[So] Fuente:Int J Behav Med;22(3):384-92, 2015 Jun.
[Is] ISSN:1532-7558
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Sub-Saharan Africa has the highest global prevalence of HIV, and the prevention of transmission between HIV-seropositive and -serodiscordant sexual partners is a critical component of HIV prevention efforts. Behavioral interventions that have demonstrated efficacy in reducing risk behaviors associated with HIV transmission and infection and have been translated, or adapted, to a variety of settings. PURPOSE: This manuscript examined implementation of behavioral interventions within resource limited health care delivery settings, and their adoption and integration within service programs to achieve sustainability. METHODS: The CDC/Partner Program, an evidence-based risk reduction intervention, was implemented in Community Health Centers (CHCs) in Zambia using a staged technology transfer process, the Training the Trainers Model. Provincial workshops and training workshops on the provision of the intervention were used to establish a cadre of trainers to provide on-site intervention facilitators capable of ultimately providing coverage to over 300 CHCs. RESULTS: CHC staff provided the intervention to clinic attendees in four provinces over 4 years while also training new facilitators. The implementation process addressed multi-level issues within the context of training, consultants, decision making, administration, and evaluation as well as practical considerations surrounding travel, training, staff compensation and ongoing quality assurance. CONCLUSIONS: The majority of challenges to implementation and maintenance were addressed and resolved, with the exception of structural limitations related to restricted resources for personnel and funding. Strengths of the program included its collaborative structure, active program leadership, commitment and support at the provincial level, the use of task shifting by existing clinic staff, the train the trainer model and ongoing quality control. Enhanced infrastructure is needed in for future implementation, such as training centers within each province, certified expert coaches and annual workshops and system changes to ensure available staff.
[Mh] Términos MeSH primario: Infecciones por VIH/prevención & control
Conducta de Reducción del Riesgo
Parejas Sexuales
[Mh] Términos MeSH secundario: África del Sur del Sahara
Femenino
Humanos
Liderazgo
Masculino
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mes de ingreso:1512
[Cu] Fecha actualización por clase:160122
[Lr] Fecha última revisión:160122
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:150530
[St] Status:MEDLINE
[do] DOI:10.1007/s12529-014-9397-3


  6 / 289008 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
PubMed Central Texto completo
Texto completo
[PMID]:25624326
[Au] Autor:Luque AE; Cohn SE; Park JG; Cramer Y; Weinberg A; Livingston E; Klingman KL; Aweeka F; Watts DH
[Ad] Dirección:University of Rochester School of Medicine and Dentistry, Rochester, New York, USA amneris_luque@urmc.rochester.edu....
[Ti] Título:Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study.
[So] Fuente:Antimicrob Agents Chemother;59(4):2094-101, 2015 Apr.
[Is] ISSN:1098-6596
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:We conducted an open-label, steady-state pharmacokinetic (PK) study of drug-drug interactions between depot medroxyprogesterone acetate (DMPA) and twice-daily lopinavir (LPV) plus low-dose ritonavir (RTV) (LPV/r) among 24 HIV-infected women and compared the results to those for HIV-infected women receiving DMPA while on no antiretroviral therapy or on nucleosides only (n = 14 subjects from the control arm of AIDS Clinical Trials Group [ACTG] study 5093). The objectives of the study were to address the effect of LPV/r on DMPA and to address the effect of DMPA on LPV/r therapy. PK parameters were estimated using noncompartmental analysis with between-group comparisons of medroxyprogesterone acetate (MPA) PKs and within-subject comparisons of LPV and RTV PKs before and 4 weeks after DMPA dosing. Plasma progesterone concentrations were measured every 2 weeks after DMPA dosing through week 12. Although the MPA area under the concentration-time curve and maximum concentration of drug in plasma were statistically significantly increased in the study women on LPV/r compared to those in the historical controls, these increases were not considered clinically significant. There were no changes in LPV or RTV exposure after DMPA. DMPA was well tolerated, and suppression of ovulation was maintained. (This study has been registered at ClinicalTrials.gov under registration no. NCT01296152.).
[Mh] Términos MeSH primario: Anticonceptivos Sintéticos Orales/efectos adversos
Anticonceptivos Sintéticos Orales/farmacología
Infecciones por VIH/quimioterapia
Inhibidores de la Proteasa VIH/efectos adversos
Inhibidores de la Proteasa VIH/uso terapéutico
Lopinavir/efectos adversos
Lopinavir/uso terapéutico
Acetato de Medroxiprogesterona/efectos adversos
Acetato de Medroxiprogesterona/farmacología
Ritonavir/efectos adversos
Ritonavir/uso terapéutico
[Mh] Términos MeSH secundario: Adolescente
Preparaciones de Acción Retardada
Interacciones de Drogas
Femenino
Infecciones por VIH/virología
Inhibidores de la Proteasa VIH/farmacocinética
Humanos
Lopinavir/farmacocinética
Mediana Edad
Ovulación/efectos de drogas
Progesterona/sangre
Ritonavir/farmacocinética
Adulto Joven
[Pt] Tipo de publicación:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nombre de substancia:
0 (Contraceptives, Oral, Synthetic); 0 (Delayed-Action Preparations); 0 (HIV Protease Inhibitors); 2494G1JF75 (Lopinavir); 4G7DS2Q64Y (Progesterone); C2QI4IOI2G (Medroxyprogesterone Acetate); O3J8G9O825 (Ritonavir)
[Em] Mes de ingreso:1512
[Cu] Fecha actualización por clase:160122
[Lr] Fecha última revisión:160122
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:150312
[St] Status:MEDLINE
[do] DOI:10.1128/AAC.04701-14


  7 / 289008 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
PubMed Central Texto completo
Texto completo
[PMID]:25444812
[Au] Autor:Miller E; Spadaccia M; Sabado R; Chertova E; Bess J; Trubey CM; Holman RM; Salazar A; Lifson J; Bhardwaj N
[Ad] Dirección:Icahn School of Medicine at Mount Sinai, Division of Infectious Diseases, New York, NY, USA. Electronic address: elizabeth.a.miller@mssm.edu....
[Ti] Título:Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy.
[So] Fuente:Vaccine;33(2):388-95, 2015 Jan 3.
[Is] ISSN:1873-2518
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:Therapeutic interventions for HIV-1 that successfully augment adaptive immunity to promote killing of infected cells may be a requisite component of strategies to reduce latent cellular reservoirs. Adoptive immunotherapies utilizing autologous monocyte-derived dendritic cells (DCs) that have been activated and antigen loaded ex vivo may serve to circumvent defects in DC function that are present during HIV infection in order to enhance adaptive immune responses. Here we detail the clinical preparation of DCs loaded with autologous aldrithiol-2 (AT-2)-inactivated HIV that have been potently activated with the viral mimic, Polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose (Poly-ICLC). HIV is first propagated from CD4+ T cells from HIV-infected donors and then rendered non-replicative by chemical inactivation with aldrithiol-2 (AT-2), purified, and quantified. Viral inactivation is confirmed through measurement of Tat-regulated ß-galactosidase reporter gene expression following infection of TZM-bl cells. In-process testing for sterility, mycoplasma, LPS, adventitious agents, and removal of AT-2 is performed on viral preparations. Autologous DCs are generated and pulsed with autologous AT-2-inactivated virus and simultaneously stimulated with Poly-ICLC to constitute the final DC vaccine product. Phenotypic identity, maturation, and induction of HIV-specific adaptive immune responses are confirmed via flow cytometric analysis of DCs and cocultured autologous CD4+ and CD8+ T cells. Lot release criteria for the DC vaccine have been defined in accordance with Good Manufacturing Practice (GMP) guidelines. The demonstrated feasibility of this approach has resulted in approval by the FDA for investigational use in antiretroviral (ART) suppressed individuals. We discuss how this optimized DC formulation may enhance the quality of anti-HIV adaptive responses beyond what has been previously observed during DC immunotherapy trials for HIV infection.
[Mh] Términos MeSH primario: Vacunas contra el SIDA/química
Vacunas contra el SIDA/inmunología
Inmunidad Adaptativa
Carboximetilcelulosa de Sodio/análogos & derivados
Células Dendríticas/inmunología
VIH-1/inmunología
Poli I-C/inmunología
Polilisina/análogos & derivados
[Mh] Términos MeSH secundario: 2,2'-Dipiridil/análogos & derivados
Linfocitos T CD4-Positivos/inmunología
Linfocitos T CD4-Positivos/virología
Linfocitos T CD8-positivos/inmunología
Línea Celular
Disulfuros
Infecciones por VIH/inmunología
Infecciones por VIH/terapia
VIH-1/crecimiento & desarrollo
VIH-1/aislamiento & purificación
VIH-1/fisiología
Humanos
Inmunoterapia Adoptiva/métodos
Polilisina/inmunología
Inactivación de Virus
beta-Galactosidasa/genética
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (AIDS Vaccines); 0 (Disulfides); 2127-03-9 (2,2'-dipyridyl disulfide); 24939-03-5 (Poly I-C); 25104-18-1 (Polylysine); 551W113ZEP (2,2'-Dipyridyl); 59789-29-6 (poly ICLC); 9004-32-4 (Carboxymethylcellulose Sodium); EC 3.2.1.23 (beta-Galactosidase)
[Em] Mes de ingreso:1601
[Cu] Fecha actualización por clase:160103
[Lr] Fecha última revisión:160103
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:141220
[St] Status:MEDLINE


  8 / 289008 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:26744804
[Au] Autor:Siripong P; Duangporn P; Takata E; Tsutsumi Y
[Ad] Dirección:Department of Biology, Faculty of Science, Naresuan University, Muang, Phitsanulok 65000, Thailand....
[Ti] Título:Phosphoric acid pretreatment of Achyranthes aspera and Sida acuta weed biomass to improve enzymatic hydrolysis.
[So] Fuente:Bioresour Technol;203:303-8, 2016 Mar.
[Is] ISSN:1873-2976
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:Achyranthes aspera and Sida acuta, two types of weed biomass are abundant and waste in Thailand. We focus on them as novel feedstock for bio-ethanol production because they contain high-cellulose content (45.9% and 46.9%, respectively) and unutilized material. Phosphoric acid (70%, 75%, and 80%) was employed for the pretreatment to improve by enzymatic hydrolysis. The pretreatment process removed most of the xylan and a part of the lignin from the weeds, while most of the glucan remained. The cellulose conversion to glucose was greater for pretreated A. aspera (86.2±0.3%) than that of the pretreated S. acuta (82.2±1.1%). Thus, the removal of hemicellulose significantly affected the efficiency of the enzymatic hydrolysis. The scanning electron microscopy images showed the exposed fibrous cellulose on the cell wall surface, and this substantial change of the surface structure contributed to improving the enzyme accessibility.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1601
[Sb] Subgrupo de revista:IM
[St] Status:In-Data-Review


  9 / 289008 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
[PMID]:26757543
[Au] Autor:Li J; Wang W
[Ti] Título:[Progress in the study of HIV capsid structure and drug discovery].
[So] Fuente:Yao Xue Xue Bao;50(9):1088-95, 2015 Sep.
[Is] ISSN:0513-4870
[Cp] País de publicación:China
[La] Idioma:chi
[Ab] Resumen:The HIV-1 capsid protein plays a crucial role in viral infectivity, assembling into a fullerene cone that encloses the viral RNA and it has gained attention as a promising therapeutic target. Research has been focused on the spatial structures of capsid proteins in recent years, and peptides and small molecules targeting capsid have been discovered. In this article, it summarizes the structure information of capsid protein, analyzes and compares the binding information of different peptides and small molecules targeting capsid. At the same time we give the perspective to the future drug discovery based on the protein-protein interaction during the maturation process.
[Mh] Términos MeSH primario: Cápsida/química
Descubrimiento de Drogas
VIH-1/química
[Mh] Términos MeSH secundario: Infecciones por VIH/quimioterapia
[Pt] Tipo de publicación:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Em] Mes de ingreso:1601
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:160113
[St] Status:MEDLINE


  10 / 289008 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Registro de Ensayos Clínicos
Texto completo
[PMID]:26624850
[Au] Autor:Molina JM; Capitant C; Spire B; Pialoux G; Cotte L; Charreau I; Tremblay C; Le Gall JM; Cua E; Pasquet A; Raffi F; Pintado C; Chidiac C; Chas J; Charbonneau P; Delaugerre C; Suzan-Monti M; Loze B; Fonsart J; Peytavin G; Cheret A; Timsit J; Girard G; Lorente N; Préau M; Rooney JF; Wainberg MA; Thompson D; Rozenbaum W; Doré V; Marchand L; Simon MC; Etien N; Aboulker JP; Meyer L; Delfraissy JF; ANRS IPERGAY Study Group
[Ad] Dirección:From the Departments of Infectious Diseases (J.-M.M., C.P., P.C., B.L., W.R.) and Sexually Transmitted Diseases (J.T.), and the Laboratories of Virology (C.D.) and Biochemistry (J.F.), Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université de Paris Diderot, Sorbonne Paris Cité, INSERM UMR 941, Department of Infectious Diseases, Hôpital Tenon (G.Pialoux, J.C.), Collège des Universitaires de Maladies Infectieuses et Tropicales (F.R.), Laboratoire de Toxicologie et Pharmacologie, Centre Hospitalier Bichat-Claude Bernard (G.Peytavin), Collège d'Etudes Mondiales (G.G.), France Recherche Nord et Sud Sida-HIV et Hépatites (V.D., L.Marchand, M.-C.S., N.E., J.-F.D.), Université de Paris Sud, Kremlin Bicêtre (L.Meyer), Paris, INSERM SC10 US19, Villejuif (C. Capitant, I.C., J.-P.A., L.Meyer), Department of Medicine, INSERM UMR 912 SESSTIM, Marseille (B.S., M.S.-M., N.L.), Department of Infectious Diseases, Hôpital de la Croix Rousse, Centre Hospitalier et Universitaire de Lyon (L.C., C. Chidiac), and Groupe de Recherche en Psychologie Sociale EA 4163, University of Lumière (M.P.), Lyon, Department of Infectious Diseases, Hôpital de l'Archet, Centre Hospitalier de Nice, Nice (E.C.), Department of Infectious Diseases, Hôpital G. Dron, Centre Hospitalier Universitaire de Tourcoing, Lille (A.P., A.C.), and Association AIDES, Pantin (J.-M.L.G.) - all in France; Centre Hospitalier de l'Université de Montréal (C.T.), Institut de Recherche en Santé Publique de l'Université de Montréal (G.G.), McGill University AIDS Centre, Jewish General Hospital (M.A.W.), and Association REZO (D.T.) - all in Montreal; and Gilead Sciences, Foster City, CA (J.F.R.).
[Ti] Título:On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
[So] Fuente:N Engl J Med;373(23):2237-46, 2015 Dec 3.
[Is] ISSN:1533-4406
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Antiretroviral preexposure prophylaxis has been shown to reduce the risk of human immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting results have been reported among studies, probably due to challenges of adherence to a daily regimen. METHODS: We conducted a double-blind, randomized trial of antiretroviral therapy for preexposure HIV-1 prophylaxis among men who have unprotected anal sex with men. Participants were randomly assigned to take a combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or placebo before and after sexual activity. All participants received risk-reduction counseling and condoms and were regularly tested for HIV-1 and HIV-2 and other sexually transmitted infections. RESULTS: Of the 414 participants who underwent randomization, 400 who did not have HIV infection were enrolled (199 in the TDF-FTC group and 201 in the placebo group). All participants were followed for a median of 9.3 months (interquartile range, 4.9 to 20.6). A total of 16 HIV-1 infections occurred during follow-up, 2 in the TDF-FTC group (incidence, 0.91 per 100 person-years) and 14 in the placebo group (incidence, 6.60 per 100 person-years), a relative reduction in the TDF-FTC group of 86% (95% confidence interval, 40 to 98; P=0.002). Participants took a median of 15 pills of TDF-FTC or placebo per month (P=0.57). The rates of serious adverse events were similar in the two study groups. In the TDF-FTC group, as compared with the placebo group, there were higher rates of gastrointestinal adverse events (14% vs. 5%, P=0.002) and renal adverse events (18% vs. 10%, P=0.03). CONCLUSIONS: The use of TDF-FTC before and after sexual activity provided protection against HIV-1 infection in men who have sex with men. The treatment was associated with increased rates of gastrointestinal and renal adverse events. (Funded by the National Agency of Research on AIDS and Viral Hepatitis [ANRS] and others; ClinicalTrials.gov number, NCT01473472.).
[Mh] Términos MeSH primario: /uso terapéutico
Infecciones por VIH/prevención & control
VIH-1
Homosexualidad Masculina
Profilaxis Pre-Exposición
/uso terapéutico
[Mh] Términos MeSH secundario: Adulto
Condones/utilización
Método Doble Ciego
Quimioterapia Combinada
/efectos adversos
Humanos
Estimación de Kaplan-Meier
Masculino
Cumplimiento de la Medicación
Mediana Edad
Factores de Riesgo
Conducta Sexual
Enfermedades de Transmisión Sexual/epidemiología
/efectos adversos
[Pt] Tipo de publicación:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
99YXE507IL (Tenofovir); G70B4ETF4S (Emtricitabine)
[Em] Mes de ingreso:1512
[Cu] Fecha actualización por clase:160122
[Lr] Fecha última revisión:160122
[Sb] Subgrupo de revista:AIM; IM
[Da] Fecha de ingreso para procesamiento:151203
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMoa1506273



página 1 de 28901 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud